文献速递皮肤肿瘤

法国晚期皮肤黑色素瘤真实世界治疗模式与临床结局

Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-10-17

结果显示中位OS为16个月(95%CI 14-18),较2007年MELODY研究延长4个月,BRAF突变者获益更明显。

要点

  • 一线治疗依BRAF状态而异:突变者74.8%用BRAF抑制剂,野生型79.3%用传统化疗。
  • 中位OS为16个月(95%CI 14-18),较2007年研究延长4个月。
  • 序贯使用BRAF抑制剂和ipilimumab者中位OS达28个月。

核心结论

  • 无论BRAF突变状态,晚期黑色素瘤患者中位OS为16个月(95%CI 14-18),较2007年MELODY研究延长4个月。
  • BRAF突变患者中位OS为18个月,野生型为14个月。
  • 序贯接受BRAF抑制剂和ipilimumab的患者中位OS为28个月,提示该治疗顺序的获益。

研究设计与样本

  • AMEL研究为多中心回顾性病历回顾研究,由33个治疗中心的33名医生参与。

主要发现

  • 94.7%的患者接受一线抗肿瘤药物治疗,62.5%接受二线治疗,26.9%接受三线治疗。
  • BRAF突变患者(50.4%)与野生型患者(47.0%)接受三线治疗的比例无显著差异。
  • 一线治疗依BRAF状态不同:突变者74.8%接受BRAF抑制剂,野生型79.3%接受传统化疗。
  • 二线及以上治疗模式更异质,取决于BRAF突变、既往治疗、疾病进展速度及免疫治疗可及性。

临床怎么用

  • 真实世界中晚期黑色素瘤一线治疗选择需依据BRAF突变状态。
  • 序贯使用BRAF抑制剂和ipilimumab可能带来生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2011, the management of advanced melanoma has radically changed with the availability of new therapies (immunotherapy and BRAF-targeted therapy) and with BRAF testing. OBJECTIVES: Following the introduction of these new therapies, the objectives of this AMEL study were to describe treatment patterns and evaluate overall survival (OS) among unresectable stage III/IV melanoma patients, in a real-life setting in France. METHODS: The AMEL study is a multicentre retrospective record review study. Thirty-three physicians working in 33 unique treatment centres participated in the study. Two hundred and sixty-four patients diagnosed between 1 January 2012 and 31 October 2012 with unresectable stage III/IV melanoma were included in the study. RESULTS: 94.7% of the patients received a first-line antitumour drug treatment, 62.5% a second-line treatment while 26.9% received a third-line treatment with no significant differences between patients with a BRAF mutation (50.4%) and BRAF wild type (47.0%). First-line treatment differs according to the BRAF status: 74.8% of patients with a BRAF mutation received a BRAF inhibitor while 79.3% of the BRAF wild-type patients were treated with conventional chemotherapy. In second line and over, the treatment patterns were more heterogeneous, depending on the BRAF mutation, the treatment received previously, the speed of progression of the disease and the availability of immunotherapy at the time the treatment was initiated. CONCLUSION: Regardless of the BRAF mutation status, the median OS of patients was 16 months (95% CI = 14-18). Compared to a similar study conducted in 2007 (MELODY), a gain of 4 months is observed. The gain seems to be higher for patients with a BRAF mutation (18 months) than for those without a BRAF mutation (14 months). The OS of patients who sequentially received both a BRAF inhibitor and ipilimumab (28 months) highlights the benefit of this treatment sequence.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Sassolas B, Leccia MT, Godard C, et al. Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France. J Eur Acad Dermatol Venereol. 2017. PMID: 28960564. doi:10.1111/jdv.14606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。